Structure Therapeutics Stock Jumps on Positive Data for Experimental Obesity Pill

Shares of Structure Therapeutics rose over 30% on promising data for its experimental obesity pill
The pill helped overweight participants lose up to 10 pounds on average in a 4-week trial
Structure plans to test the pill in longer mid-stage trials for diabetes and obesity
The pill is in the same class as Novo Nordisk's Ozempic and Wegovy drugs
Analysts say cheaper, convenient pill versions could expand the obesity drug market

cnbc.com

Relevant topic timeline:

8/8/2023

Wegovy shown to cut risk of stroke and heart attacks, company says

Main Topic: The obesity drug Wegovy reduces the risk of cardiovascular events by 20%. Key Points: 1. Wegovy, a weight-loss drug, has been found to have medical benefits beyond weight reduction. 2. The drug cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%. 3. The results may lead to insurance companies providing coverage for Wegovy, which is currently perceived as a lifestyle medication.

9/5/2023

Weight-Loss Drug Stocks Are Soaring. Why There’s More Room to Run.

Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.

9/7/2023

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.

Eli Lilly could potentially generate $50 billion in annual sales from weight-loss drugs by 2030, positioning the pharmaceutical company as a major beneficiary in the obesity treatment market, according to J.P. Morgan.

9/22/2023

Obesity Drug Market Set to Boom as New Medications Gain Traction

The global market for weight-loss drugs is projected to reach $100 billion by 2035, with revenue in the US potentially reaching as high as $70 billion alone.

9/29/2023

Spending on Ads for Diabetes Drugs Jumps 20% in 2022, Totaling Nearly $500 Million

Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, with Novo Nordisk's Ozempic and Wegovy leading the pack.

10/24/2023

Coca-Cola Likely Spared from Diabetes Drug Fallout; JPMorgan Bullish on Novo Nordisk and Food Delivery

JPMorgan analysts predict that emerging weight-loss drugs could create a $100 billion-plus opportunity, with the GLP-1 category expected to exceed $100 billion in annual sales over time, split between diabetes and obesity, and a global market estimate of over $140 billion by 2032.

Topics

Posted 9/29/2023, 4:02:36 PM